Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Endocrinology
Volume 2018, Article ID 7925019, 3 pages
Case Report

Successful Treatment of Acromegaly and Associated Hypogonadism with First-Line Clomiphene Therapy

1Diabetes & Endocrinology Institute at Renaissance, Edinburg, TX 78539, USA
2Division of Neurosurgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA
3Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL 33136, USA

Correspondence should be addressed to Atil Y. Kargi; ude.imaim.dem@igraka

Received 27 February 2018; Accepted 23 May 2018; Published 26 June 2018

Academic Editor: John Broom

Copyright © 2018 Juan D. Palacios et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Clomiphene citrate (CC) has been reported as an effective add-on therapy to somatostatin analogs and dopamine agonists in patients with acromegaly accompanied by hypogonadism; its use as a single agent to treat acromegaly and associated hypogonadism following incomplete surgery has not been previously reported. We report the first case in which clomiphene was utilized as a single agent for the dual management of acromegaly and hypogonadism, not controlled by pituitary surgery alone. The treatment was well tolerated and proved to be effective after a process of treatment withdrawal and reintroduction. We propose that clomiphene may be considered as a cost-effective oral treatment option in select cases of hypogonadal acromegaly.